Rapport Therapeutics reported positive topline Phase II data for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator for focal onset seizures. The drug reduced clinical seizure frequency by nearly 78%, substantially exceeding expectations and biomarkers of electrographic seizures showed similar improvements. Following these results, the company anticipates progressing RAP-219 into multiple Phase III trials starting next year. The findings have substantially increased market confidence, doubling the company’s market valuation.